# Pizarra — PT-pseudo_175e6ad47991 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_175e6ad47991
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 79-year-old male
  - PSA: 28.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.28 ng/mL²
  - PSA velocity: 2.75 ng/mL/yr
  - Prior PSA: 16.6 ng/mL
  - Prostate volume: 100.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.3807473 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 28 ng/mL. PI-RADS 5. PSAD 0.28. Prostate volume 100 mL. csPCa 0.38.

Vitals: weight 88 kg, height 183 cm, BMI 26.3, BP 130/64 mmHg, HR 84 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2002).

Chief complaint: Evaluation of a marked serum prostate-specific antigen increase to 28.0 ng/mL alongside reassessment of previously negative biopsy results.

History: Residing in a ground-floor apartment with his wife, the seventy-nine-year-old retired warehouse worker first came to attention regarding a prostate-specific antigen elevation documented in mid-2022. He maintains a steady lifestyle featuring weekly swimming sessions and moderate alcohol intake averaging 20 units weekly. Mild lower urinary tract symptoms are present, corresponding to an IPSS score of 9, though acute urinary retention and haematuria are absent. Past medical history remains clear save for an appendectomy performed in his youth and a recent routine cognitive screening at a memory clinic. Ex-smoker (30 pack-yr, quit 2002). Participation in any prostate cancer research trials was previously declined. Comorbidities are absent, and he takes no active medications.

Physical examination: DRE: Normal. Prostate is symmetrically enlarged with smooth, firm consistency and no palpable asymmetry or discrete nodules. General examination remains within normal limits, featuring stable vitals and absent lymphadenopathy or bone tenderness. Abdominal palpation is soft and non-tender, with a palpable bladder correlating with the documented prostate volume.

Patient info: retired warehouse worker; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 20 units / week; exercise Swimming 1x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Audiology — hearing test; Memory clinic — baseline screening.
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.59 +/- 0.21   (95% CI 0.16-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.19  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.09  (few labelled cases resemble this one)
  - 3.6 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=1.0, psa=28.0, age=79.0, psad=0.28, dre_ord=0.0, vol=100.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (2.75 ng/mL/yr) against the high PI-RADS score (5) and the high PSA level (28.0 ng/mL). It also could not incorporate the context of the prior negative biopsy result, which is a critical piece of information for re-evaluation. Finally, it did not see the full laboratory panel or the MRI report details, which might provide context on the aggressiveness suggested by the PI-RADS 5.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests 'BIOPSY' with a wide interval (0.59 +/- 0.21), indicating it is in the 'discuss' tier. A failure mode is the contradiction between the high PI-RADS 5 and the prior negative biopsy result, which might suggest the prior negative result was overly reassuring or the current findings are atypical. Another failure mode is the high PSA velocity (2.75 ng/mL/yr) combined with the high PSA level (28.0 ng/mL), which might push the decision towards biopsy despite the prior negative result.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <laboratory results> -> <the full panel> -> <If labs show significant inflammation or other markers, it might change the risk assessment.>
  <PSA history (trend)> -> <The full PSA trajectory> -> <If the trend is highly concerning (e.g., rapid rise), it strengthens the case for biopsy.>
  <radiology / mpMRI report> -> <The full mpMRI prose> -> <The detailed description of the lesion characteristics is crucial for interpreting the PI-RADS 5.>
  <previous GP / urology consultation notes> -> <Notes from prior evaluation> -> <These notes might contain context regarding the initial negative biopsy interpretation.>

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number.
  
  **mpMRI Report:**
  "PI-RADS 5 lesion in the right posterior peripheral zone (base-to-mid), approximately 25 mm. Prostate volume: 100.0 mL. PSA density: 0.28 ng/mL/mL. csPCa predicted probability 0.3807473."
  
  **PSA Trend:**
  [{"date": "Jun 2022", "val": 2.5}, {"date": "Feb 2023", "val": 4.7}, {"date": "Sep 2023", "val": 8.9}, {"date": "May 2024", "val": 16.8}, {"date": "Jan 2025", "val": 28.0}]
  
  **Laboratory Results:**
  {"name": "PSA", "val": "28.0 ng/mL", "date": "30 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.34 ng/mL", "date": "30 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "30 Nov 2024", "flag": "L"}
  
  **Previous Notes:**
  {"date": "08 May 2024", "author": "Dr. L. Smits (GP)", "text": "Clinical records indicate a review for sustained prostate-specific antigen elevation. Earlier testing in September 2023 registered 18.3 ng/mL, while the most recent assay on 08 May 2024 showed 16.6 ng/mL. Following review of this trend and the prior biopsy bucket \"Negative\", a repeat serum test was ordered alongside standard chemistry panels. Results were communicated, and coordination for a urology outpatient visit was initiated."}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PI-RADS 5 lesion in the right posterior peripheral zone (base-to-mid), approximately 25 mm.
  - PSA velocity of 2.75 ng/mL/yr (calculated from trend data).
  - PSA level of 28.0 ng/mL.
  - Prior biopsy result was Negative.
  
  AGAINST sampling this patient now:
  - Prior biopsy result was Negative.

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5) and the concerning PSA velocity, which contradicts the prior negative biopsy. This leans towards a strong recommendation for biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to the high-risk PI-RADS 5 lesion and the concerning PSA velocity of 2.75 ng/mL/yr, which contradicts the prior negative biopsy result. The decisive factors driving this decision are the PI-RADS 5 score and the PSA velocity, which together indicate a high likelihood of clinically significant prostate cancer progression despite the prior negative finding.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
